Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis
Authors:
- 6 October 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 77 (1) , 174-180
Abstract
Telavancin is a lipoglycopeptide antibiotic with limited pharmacokinetic data to guide drug dosing in patients receiving haemodialysis. This study characterized telavancin pharmacokinetics in patients receiving haemodialysis. This was a Phase IV, prospective, open-label, single-centre, crossover pharmacokinetic study (ClinicalTrials.gov: NCT02392208). Eight subjects with end-stage kidney disease requiring maintenance haemodialysis (mean ± SD: 47 ± 20 years, 69.5 ± 17.1 kg) received 5 mg/kg telavancin IV 3 h before starting a 3.5 hour haemodialysis treatment with a high-permeability haemodialyser (haemodialysis period). After a 14 day washout period, a second 5 mg/kg dose was administered post-haemodialysis (control period). Telavancin plasma concentrations were measured over a 2 day period after each dose and non-compartmental pharmacokinetic analyses were performed. The geometric mean (GM) of telavancin overall clearance was 11.2 mL/h/kg (intrinsic clearance and dialytic clearance) in the haemodialysis period and 5.9 mL/h/kg (off-haemodialysis clearance) in the control period [GM ratio (GMR) = 1.89; 90% CI: 1.70–2.10; P < 0.01]. The GM t½ was 13.1 h when haemodialysis occurred 3 h post-dosing in the haemodialysis period but extended to 20.9 h with post-haemodialysis dosing in the control period (GMR = 0.63; 90% CI: 0.54–0.73; P < 0.01). The GM of telavancin plasma concentrations removed by haemodialysis was 27.7%. The GMR of peak plasma concentration and volume of distribution of the haemodialysis period and the control period were 0.88 (90% CI: 0.79–0.98; P = 0.08) and 1.17 (90% CI: 1.05–1.30; P = 0.048), respectively. Haemodialysis with high-permeability haemodialysers removes telavancin considerably (∼⅓ of body load). Telavancin 5 mg/kg every 48 h post-haemodialysis dosing is recommended, but dose adjustments may be warranted if haemodialysis starts within 3 h of telavancin administration.Keywords
Funding Information
- Theravance Biopharma, Inc
This publication has 20 references indexed in Scilit:
- Telavancin Pharmacokinetics and Pharmacodynamics in Patients with Complicated Skin and Skin Structure Infections and Various Degrees of Renal FunctionAntimicrobial Agents and Chemotherapy, 2012
- Pharmacodynamics of Telavancin Studied in an In Vitro Pharmacokinetic Model of InfectionAntimicrobial Agents and Chemotherapy, 2011
- Mass Balance and Pharmacokinetics of [ 14 C]Telavancin following Intravenous Administration to Healthy Male VolunteersAntimicrobial Agents and Chemotherapy, 2010
- Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemiaJournal of Antimicrobial Chemotherapy, 2010
- Staphylococcus aureus Infections in HemodialysisClinical Journal of the American Society of Nephrology, 2009
- Intradialytic Administration of Daptomycin in End Stage Renal Disease Patients on HemodialysisClinical Journal of the American Society of Nephrology, 2009
- Pharmacodynamic Effects of Telavancin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Strains in the Presence of Human Albumin or Serum and in an In Vitro Kinetic ModelAntimicrobial Agents and Chemotherapy, 2007
- Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 μg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysisClinical Therapeutics, 2006
- Mortality differences among organisms causing septicemia in hemodialysis patientsHemodialysis International, 2006
- I. NKF-K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy: Update 2000American Journal of Kidney Diseases, 2001